A Phase II of Entospletinib, a SYK Inhibitor, First line cGVHD patients

Clinical Trial Grant

Duke Scholars

Principal Investigator Stefanie Sarantopoulos Medicine, Hematologic Malignancies and Cellular Therapy

Administered By

Duke Cancer Institute

Awarded By

Gilead Sciences, Inc.

Start Date

May 31, 2016

End Date

March 22, 2019

Administered By

Duke Cancer Institute

Awarded By

Gilead Sciences, Inc.

Start Date

May 31, 2016

End Date

March 22, 2019